The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

References

• Zhang J, Li H, Gao D, Zhang B, Zheng M, Lun M, Wei M, Duan R, Guo M, Hua J, et al. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biol Ther. 2018;19:475–483. doi:10.1080/15384047.2018.1433501.
   PubMed Web of Science ®Google Scholar
• Meyer T, Palmer DH, Cheng AL, Hocke J, Loembe AB, Yen CJ. mRECIST to predict survival in advanced hepatocellular carcinoma: analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int. 2017;37:1047–1055. doi:10.1111/liv.13359.
   PubMed Web of Science ®Google Scholar
• Covey AM, Hussain SM. Liver-directed therapy for hepatocellular carcinoma: an overview of techniques, outcomes, and posttreatment imaging findings. AJR Am J Roentgenol. 2017;209:67–76. doi:10.2214/AJR.17.17799.
   PubMed Web of Science ®Google Scholar
• Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9:6075–6081. doi:10.2147/DDDT.S97235.
   PubMed Web of Science ®Google Scholar
• de Baere T, Tselikas L, Yevich S, Boige V, Deschamps F, Ducreux M, Goere D, Nguyen F, Malka D. The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer. 2017;75:231–242. doi:10.1016/j.ejca.2017.01.010.
   PubMed Web of Science ®Google Scholar
• Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1alpha and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8:297–302. doi:10.14740/jocmr2496w.
   PubMedGoogle Scholar
• Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523–529. doi:10.1080/02841850801958890.
   PubMed Web of Science ®Google Scholar
• Du H, Zhao J, Hai L, Wu J, Yi H, Shi Y. The roles of vasohibin and its family members: beyond angiogenesis modulators. Cancer Biol Ther. 2017;18:827–832. doi:10.1080/15384047.2017.1373217.
   PubMed Web of Science ®Google Scholar
• Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist. 2009;14:70–76. doi:10.1634/theoncologist.2008-0191.
   PubMed Web of Science ®Google Scholar
• Bruix J, Tak W-Y, Gasbarrini A, Santoro A, Colombo M, Lim H-Y, Mazzaferro V, Wiest R, Reig M, Wagner A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49:3412–3419. doi:10.1016/j.ejca.2013.05.028.
   PubMed Web of Science ®Google Scholar
• Han T, Luan Y, Xu Y, Yang X, Li J, Liu R, Li Q, Zheng Z. Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review. Cancer Biol Ther. 2017;18:635–639. doi:10.1080/15384047.2017.1345394.
   PubMed Web of Science ®Google Scholar
• Lu W, Jin X-L, Yang C, Du P, Jiang F-Q, Ma J-P, Yang J, Xie P, Zhang Z. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther. 2017;18:433–438. doi:10.1080/15384047.2017.1323589.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa0708857.
   PubMed Web of Science ®Google Scholar
• Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914–921. doi:10.1111/j.1572-0241.2007.01712.x.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371. doi:10.1038/nrm1911.
   PubMed Web of Science ®Google Scholar
• Lin D, Wang Z, Li J, Wang L, Wang S, Hu G-X, Liu X. The effect of apatinib on the metabolism of carvedilol both in vitro and in vivo. Pharmacology. 2016;97:31–37. doi:10.1159/000441228.
   PubMed Web of Science ®Google Scholar
• Wu J, Li A, Yang J, Lu Y, Li J. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. Onco Targets Ther. 2017;10:2761–2768. doi:10.2147/OTT.S131022.
   PubMed Web of Science ®Google Scholar
• Varghese J, Kedarisetty C, Venkataraman J, Srinivasan V, Deepashree T, Uthappa M, Ilankumaran K, Govil S, Reddy M, Rela M. Combination of TACE and sorafenib improves outcomes in BCLC stages B/C of hepatocellular carcinoma: a single centre experience. Ann Hepatol. 2017;16:247–254. doi:10.5604/16652681.1231583.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–3140. doi:10.1158/1535-7163.MCT-08-0013.
   PubMed Web of Science ®Google Scholar
• Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Francès C, Knebelmann B, Goldwasser F. Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf. 2010;9:275–287. doi:10.1517/14740330903510608.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2013;39:252–260. doi:10.1016/j.ctrv.2012.05.003.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219–3225. doi:10.1200/JCO.2013.48.8585.
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961–1969. doi:10.1002/ijc.28829.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454. doi:10.1200/JCO.2015.63.5995.
   PubMed Web of Science ®Google Scholar
• Liu C, Xing W, Si T, Yu H, Guo Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget. 2017;8:100734–100745. doi:10.18632/oncotarget.20140.
   PubMedGoogle Scholar
• Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. doi:10.1016/S1470-2045(08)70285-7.
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul J-L, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821–829. doi:10.1016/j.jhep.2012.06.014.
   PubMed Web of Science ®Google Scholar
• Jiang T, Cheng R, Zhang G, Su C, Zhao C, Li X, Zhang J, Wu F, Chen X, Gao G, et al. Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study. Clin Lung Cancer. 2017;18:631–9 e2. doi:10.1016/j.cllc.2017.04.015.
   PubMed Web of Science ®Google Scholar
• Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153. doi:10.1186/s13045-017-0521-0.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132.
   PubMed Web of Science ®Google Scholar
• Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, Yaghmai V. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology. 2015;62:1111–1121. doi:10.1002/hep.27915.
   PubMed Web of Science ®Google Scholar